Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids

(NASDAQ:SGHT) Sight Sciences, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a new direct practice expense supply code for the single-use TearCare SmartLids component of the TearCare System. The new supply code is SD397, and CMS has assigned it a price of $1,000 effective January 1, 2027. This code and price are part of the CY 2027 Medicare Physician Fee Schedule (PFS) Final Rule. The TearCare SmartLids are used in procedures reported with CPT code 0563T for bilateral evacuation of meibomian glands using heat delivered through wearable, open-eye eyelid treatment devices, followed by manual gland expression. CPT 0563T remains carrier-priced, and the new supply code does not establish a national Medicare payment rate or separate reimbursement for SmartLids. Payment determinations for the procedure remain subject to applicable payer coverage and reimbursement policies. Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences, stated that establishing a validated, nationally recognized supply valuation for TearCare provides greater transparency into an important direct practice expense associated with the procedure and can support more transparent and consistent reimbursement for TearCare procedures over time. The TearCare SmartLids adhere to the tarsal plates of the upper and lower eyelids and deliver a clinically-proven, highly precise, and software-controlled therapeutic temperature to melt meibomian gland obstructions while allowing patients to blink during treatment. The Sight Sciences Market Access team is available to assist with coverage, coding, and payment questions. The OMNI Surgical System is an implant-free, minimally invasive glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma and is CE Marked for use in the European Union. The SION Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The TearCare System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands.

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

Sight Sciences, Inc. (NASDAQ:SGHT) reported financial results for the first quarter ended March 31, 2026, showing total revenue of $19.7 million, a 13% increase compared to the prior year. Interventional Glaucoma revenue was $18.3 million, up 7%, and Interventional Dry Eye revenue was $1.4 million, up 244% from the prior year. The company raised its full year 2026 revenue guidance to $83.0 million to $89.0 million. Sight Sciences also announced a final judgment in its patent infringement case against Alcon, awarding $55.4 million in damages and a 10% ongoing royalty. Cash and cash equivalents totaled $85.0 million as of March 31, 2026.